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Abstract
Background:  Giant cell tumor is a benign but locally aggressive bone neoplasm which
uncommonly involves the skull. The petrous portion of the temporal bone forms a rare location
for this tumor.
Case presentation: The authors report a case of a large giant cell tumor involving the petrous
and squamous portions of the temporal bone in a 26 year old male patient. He presented with right
side severe hearing loss and facial paresis. Radical excision of the tumor was achieved but facial
palsy could not be avoided.
Conclusion: Radical excision of skull base giant cell tumor may be hazardous but if achieved is the
optimal treatment and may be curative.
Background
Giant cell tumor (GCT) of bone is an uncommon primary
bone neoplasm that usually occurs in the long bones. It is
rarely encountered in the skull where it is preferentially
seen to involve the sphenoid and the temporal bones. It is
a benign neoplasm but can be locally aggressive. A ten-
dency towards local recurrence and late malignant change
with metastases especially to the lung has been reported
[1,2]. Radical surgical removal is the preferred modality of
treatment. We present a GCT of the temporal bone in a 26




A 26 year old male was admitted with impaired hearing
and tinnitus on the right side and swelling of the right
temporal region which was gradually progressive for the
last two years. His general physical examination was nor-
mal. Neurological examination revealed a severe right
conductive hearing loss with a Grade II House-Brackman
facial nerve paresis. A diffuse swelling was noted in the
right temporal and preauricular region. CT scan of the
brain showed a large well defined hyperdense contrast
enhancing lesion originating from the right temporal
bone – squamous and petrous portions with a large
intracranial extension causing uncal herniation [Fig. 1
&2].
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Surgical management
The patient was taken up for surgery with an intention of
radical removal. Control of the right external carotid
artery (ECA) was obtained in the neck [Fig. 3 inset]. Right
frontotemporal scalp flap was raised. The temporalis mus-
cle was seen to be infiltrated by the tumor and was excised
seperately. The tumor was firm, reddish brown and vascu-
lar. It had destroyed the squamous temporal bone, lateral
petrous portion, zygomatic arch and was seen invading
the cranium pushing the temporal bone superiorly and
medially along with the dura [Fig. 3]. Dura was not trans-
gressed. Piecemeal total removal of the tumor was
achieved with temporary clamping of the right ECA. The
tumor was adherent to the dura but could be peeled off
the dura [Fig. 4]. Biopsy was taken from surrounding
bone, muscle and dura from 4 different sites. A drain was
left in the large dead space created by the removal of the
tumor. Cranioplasty was planned for a later date.
Postoperative period and follow up
Postoperatively the patient developed a right total LMN
VII nerve palsy (Grade VI House-Brackman). Hence a right
Preoperative CT scan Figure 1
Preoperative CT scan. Preoperative axial CT scan which shows a large hyperdense tumor arising from the petrous portion 
of the right temporal bone with intracranial extension and impending uncal herniation.BMC Ear, Nose and Throat Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6815/5/8
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tarsorrhaphy was done to prevent exposure keratitis one
week after the first operation. At the same sitting the
external auditory canal was also closed to prevent com-
munication of the dead space in the cranium with the
external auditory canal after confirming the absence of
any collection in the intracranial dead space. The postop-
erative period was otherwise uneventful. Histopathologi-
cal examination revealed a neoplasm composed of
numerous osteoclast like giant cells amidst a background
of mononuclear plump spindle cells suggestive of a GCT
[Fig. 5]. The histopathological examination of the other 4
areas of bone, dura and muscle did not reveal any tumor
infiltration. Postoperative CT scan confirmed a total exci-
sion of the tumor [Fig. 6]. Since a radical excision of the
tumor had been achieved it was decided to defer radio-
therapy. Three months after surgery patient was normal
but for the deafness and facial palsy. Follow up CT at 6
months and 12 months did not reveal any recurrence.
Discussion
Neoplasia of the skull bones are uncommon accounting
for only 2.4% – 2.6% of all primary bone tumors [1]. The
majority of giant cell tumors occur in the long bones usu-
ally the distal femur, proximal tibia and fibula, distal
radius and ulna [3]. The skull is a rare location for GCT. In
the cranium the sphenoid bone is the commonest site fol-
lowed by the temporal bone [1,3-8]. This can be explained
by the fact that the tumor genesis occurs in the endochon-
dral bone instead of intramembranous bone [3,5-7]. The
temporal bone has two main components – squamous
and petromastoid. The squamous portion develops by
intramembranous ossification, while the petreomastoid
portion develops from cartilage (endochondral bone).
GCTs are commonly seen to arise from the petromastoid
portion as was noted in the present case. GCT is com-
monly seen in the 30–50 years age group with only 16%
of patients below 20 years of age [6,9]. A mild female pre-
ponderance is seen but this is more pronounced in the
younger age group [9]. Typically, the tumor presents as an
enlarging mass associated with local pain over a period of
few weeks to years [9]. GCT of the sphenoid may present
with headache, visual field defects, blindness, diplopia,
second through eighth cranial nerve dysfunction, endo-
crinopathy and change of mental status [4]. Temporal
bone tumors present with pain usually behind the
affected ear, deafness and facial weakness as in the present
case [6]. Temporal bone GCT may invade the infratempo-
ral fossa, paranasal sinuses and nasopharynx [6]. Intracra-
nial extension as in our case may also be present. Dural
penetration with invasion into the brain has also been
seen [5,6]. Plain radiography shows radiolucent lesion of
the skull and cannot be generally differentiated from
other radiolucent lesions. On CT it is seen as a lytic lesion
expanding the bony cortex [10]. Generally these tumors
are contrast enhancing due to their vascular nature as seen
in our patient.
Preoperative CT scan Figure 2
Preoperative CT scan. The figure shows the sagittal and coronal reconstruction of the tumor.BMC Ear, Nose and Throat Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6815/5/8
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These tumors generally tend to expand and attenuate the
bony cortex rather than erode it [10]. GCT may be vascular
and an external carotid angiogram may be required to
demonstrate the arterial supply. In our patient the tumor
was vascular but no angiogram was performed. However,
temporary clamping of the external carotid artery during
excision reduced the intraoperative bleeding. Grossly,
these tumors are grey to yellow-brown, soft or firm and
friable. Small cystic areas and grey-white necrotic foci may
be seen. Microscopically, GCT consists of plump spindle
shaped or ovoid cells with admixed multinucleated, cyto-
logically benign giant cells. Variable numbers of benign
multinucleated cells are seen amidst sheets of benign
mononuclear spindle shaped cells with similar nuclear
features. The nuclei are generally hypochromatic with
inconspicuous nucleoli and mitotic figures are uncom-
mon [4]. Histological differentiation of GCT may be chal-
lenging. The differential diagnoses consist of central giant
cell granuloma (CGCG), aneurysmal bone cyst, chond-
roblastoma, hyperparathyroidism and fibrous dysplasia
[8]. CGCG is a reactive bone lesion that occurs mainly in
the jaws [11]. CGCG and GCT are histologically very sim-
ilar and the main significant difference is the greater
number of nuclei in the giant cells of the GCT [12,13].
CGCGs are distinguished from true GCTs by their fibro-
genic, relatively acellular stroma, extensive osseous meta-
plasia and the clustering of giant cells around areas of
hemorrhage or necrosis [5]. A key point in the differential
diagnosis is that in GCT the stromal cells and giant cells
resemble each other particularly with regard to their
Tumor exposure Figure 3
Tumor exposure. Right temporoparietal craniectomy and tumor exposure after right external carotid artery control (inset) 
and excision of the temporalis muscle. Tumor was friable, reddish brown and vascular.BMC Ear, Nose and Throat Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6815/5/8
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nuclei, whereas in giant cell reparative granuloma, the
osteoclasts and the stromal cells of the fibroblastic type
are distinctly different [14]. Jaffe has subclassified GCT
into three grades but such a grading has not been found to
correlate with subsequent tumor behaviour or sarcoma-
tous transformation [1,5].
The precise ontogeny of GCT is unresolved. GCT and
CGCG are histologically and pathogenetically similar
[15]. Cell cycle associated proteins like MDM2, Ki-67 and
PCNA have been seen to be widely expressed in CGCG
and GCT. The percentage of Ki-67 and PCNA positive cells
are higher in CGCG[11]. This means that CGCGs show a
higher proliferative activity than GCTs. GCT cells are also
seen to produce both MMP-9 and tumor necrosis factor-
alpha (TNF-alpha) [16]. Studies suggest that TNF-alpha
secreted by the multinucleated giant cells up-regulates
MMP-9 expression in GCT stromal cells by the induction
of certain transcription factors, which in turn enhanced
the rate of transcription of MMP-9 gene. An essential cell-
cell interaction in the regulation of MMP-9 expression
exists in GCT [16]. Although it is the giant cell which is the
most prominent feature of these lesions it is the mononu-
clear spindle cell which is the proliferating cell. Several
pathways to induce osteoclast like giant cell formation
from monocytes have been reported. The spindle cell
recruits monocytes and induces them to differentiate into
osteoclastic giant cells through release of cytokines
[15,17]. Receptor activator of nuclear factor kappa B
(RANK) ligand is also reported to play a crucial role in
osteoclastic cell genesis [17-19]. It is possible that the sol-
uble RANKL is released from the tumor derived cells and
After completion of tumor excision Figure 4
After completion of tumor excision. After radical excision of tumor (piecemeal) the defect is covered with gelfoam.BMC Ear, Nose and Throat Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6815/5/8
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the soluble factor interacts with RANK expressed in mono-
cytes resulting in osteoclast-like cell formation in
cooperation with macrophage colony stimulating factor
secreted from the cells [17]. SDF-1 has also been incrimi-
nated as one of the significant chemo-attractant factors
involved in the recruitment of hematopoietic osteoclast
precursor cells during tumor-induced osteoclastogenesis
[20]. The histopathogenesis of GCT and CGCG thus
appears to be identical but the biological and clinical
behavior of GCT is more aggressive than the latter.
The treatment of choice is complete surgical excision
which if achieved can be curative [1,5,9]. However the
skull base location of these tumors can make total surgical
excision hazardous and not possible [5,6]. The role of
adjuvant radiotherapy in eliminating residual tumor tis-
sue is controversial. Some authors claim that GCT is not
radiosensitive and radiation may provoke a sarcomatous
transformation in the residual tumor tissue [3,5]. How-
ever, other authors recommend a single course of moder-
ate dose super voltage radiation in achieving a high
success rate and at the same time lowering the likelihood
of malignant transformation [4-6,8]. Radiotherapy
remains the only option for unresectable tumors. In our
patient radiotherapy was deferred for the present as radi-
cal surgical excision was achieved with no residual tumor.
Microphotograph of the tumor Figure 5
Microphotograph of the tumor. Microphotograph (250×) of the specimen in H & E stains showing neoplastic stromal cells 
and multinucleated giant cells. The stromal cells (horizontal arrow) are round to spindle shaped with moderate amount of eosi-
nophilic cytoplasm and a single nucleus. They are mesenchymal in origin. The multinucleated giant cells (vertical arrow) are 
large in size with eosinophilic cytoplasm and a large number of nuclei.BMC Ear, Nose and Throat Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6815/5/8
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Treatment of GCT and CGCG with calcitonin and osteo-
protegrin has received attention. Osteoclasts express calci-
tonin receptors and can be inhibited by calcitonin. In GCT
and CGCG, tumor giant cells and their precursors also
express calcitonin receptors. Clinical studies on treatment
of CGCG with calcitonin have shown positive results
probably due to control of osteoclastogenesis [15]. Oste-
oprotegrin ligand was also selectively overexpressed in
GCTs and may indicate another possible target to which
antitumor therapy could be directed [21]. Osteoprotegrin
influences osteoclastogenesis and may be used for the
treatment of GCT and CGCG. Osteoprotegrin is a "decoy"
receptor for RANKL and therefore inhibits the RANK-
RANKL interaction, which is a necessary step in the osteo-
Postoperative CT Figure 6
Postoperative CT. Postoperative CT scan of the patient showing total excision of the tumor and the normal alignment of 
the intracranial structures.BMC Ear, Nose and Throat Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6815/5/8
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clastogenesis. This is the rationale for a probable thera-
peutic use of Osteoprotegrin. Its utility is however
unproven [15].
GCT can recur especially where only a curettage is
employed [6,7]. Prosser et al recommend primary
curettage for intraosseous giant-cell tumors without adju-
vant treatment or filling agents, but tumors with soft tis-
sue extension or with local recurrence require more
aggressive treatment [22]. Metastases occur in only 2% of
cases and are usually to the lungs but spread to rare areas
like lymph nodes, mediastinum, skin, scalp and pelvis has
been reported [2,9]. Our patient is on regular clinical fol-
low up every 3 months and 6 monthly CT scan. He is
recurrence free at the end of 12 months.
Conclusion
Giant cell tumor involving the petrous portion of the tem-
poral bone is rare. A radical excision if possible is the
optimal treatment. Adjuvant radiotherapy is controversial
and should be reserved for residual tumor and unresecta-
ble tumors. Newer modalities like calcitonin and osteo-
protegrin are being investigated.
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